Patents by Inventor Juan Carlos Almagro

Juan Carlos Almagro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Interferon beta antibodies and uses thereof
    Patent number: 11858986
    Abstract: The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFN?). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: January 2, 2024
    Assignees: Pfizer Inc., The Brigham And Women's Hospital, Inc.
    Inventors: Stefano V. Gulla, Christine Huard, Janet Elizabeth Buhlmann, Juan Carlos Almagro, Sreekumar R. Kodangattil, Steven A. Greenberg, Edward Roland Lavallie, Eric M. Bennett, Lidia Mosyak, James Perry Hall, Anthony John Coyle
  • Neutralizing human anti-CD27 antibodies
    Patent number: 11732050
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: August 22, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES
    Publication number: 20220233529
    Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor, an adenosine A2A or A2B receptor inhibitor, and a PD-1/PD-L1 inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 and/or PD-1/PD-L1 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies, PD-1/PD-L1 inhibitors, and A2A/A2B inhibitors are also disclosed.
    Type: Application
    Filed: December 29, 2021
    Publication date: July 28, 2022
    Inventors: Hui Wang, Juan Carlos Almagro, Rebecca A. Buonpane, Peter Niels Carlsen, Taisheng Huang, Yong Li, Horacio G. Nastri, Chao Qi, Shaun M. Stewart, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Jing Zhou, Wenyu Zhu
  • ANTI-CD73 ANTIBODIES AND USES THEREOF
    Publication number: 20210230293
    Abstract: Anti-CD73 antibodies are disclosed. Also disclosed are related nucleic acids, vectors, cells, and pharmaceutical compositions. Methods of treating cancer with the anti-CD73 antibodies are also disclosed.
    Type: Application
    Filed: December 30, 2020
    Publication date: July 29, 2021
    Inventors: Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane
  • CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY
    Publication number: 20210230294
    Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.
    Type: Application
    Filed: December 30, 2020
    Publication date: July 29, 2021
    Inventors: Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane, Hui Wang, Yingnan Chen, Xiaozhao Wang, Peter Niels Carlsen, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu, Taisheng Huang
  • Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
    Publication number: 20210205311
    Abstract: The present application provides methods of treating cancer using a combination of an inhibitor of A2A and/or A2B and an inhibitor of PD-1 and/or PD-L1.
    Type: Application
    Filed: December 30, 2020
    Publication date: July 8, 2021
    Inventors: Hui Wang, Juan Carlos Almagro, Rebecca A. Buonpane, Peter Niels Carlsen, Taisheng Huang, Yong Li, Luping Lin, Horacio G. Nastri, Chao Qi, Shaun M. Stewart, Pramod Unnikrishnan Thekkat, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Jing Zhou, Wenyu Zhu
  • INTERFERON BETA ANTIBODIES AND USES THEREOF
    Publication number: 20210163588
    Abstract: The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFN?). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.
    Type: Application
    Filed: November 9, 2020
    Publication date: June 3, 2021
    Inventors: Stefano V. Gulla, Christine Huard, Janet Elizabeth Buhlmann, Juan Carlos Almagro, Sreekumar R. Kodangattil, Steven A. Greenberg, Edward Roland Lavallie, Eric M. Bennett, Lidia Mosyak, James Perry Hall, Anthony John Coyle
  • Method of treating osteoarthritis with human oncostatin M antibodies
    Patent number: 10941197
    Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: March 9, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, William DuBell, Johan Fransson, Jose Pardinas, Gopalan Raghunathan
  • Interferon beta antibodies and uses thereof
    Patent number: 10829553
    Abstract: The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFN?). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 10, 2020
    Assignees: PFIZER INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Stefano V. Gulla, Christine Huard, Janet Elizabeth Buhlmann, Juan Carlos Almagro, Sreekumar R. Kodangattil, Steven A. Greenberg, Edward Roland Lavallie, Eric M. Bennett, Lidia Mosyak, James Perry Hall, Anthony John Coyle
  • Human Anti-CD27 Antibodies
    Publication number: 20200277393
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies
    Patent number: 10689453
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: June 23, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Methods of Inhibiting Activity Using Anti-CD27 Antibodies
    Publication number: 20190248910
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 15, 2019
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Methods of inhibiting T-cell mediated B-cell antibody production using anti-CD27 antibodies
    Patent number: 10301392
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: May 28, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Human Oncostatin M Antibodies and Methods of Use
    Publication number: 20190092856
    Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
    Type: Application
    Filed: December 10, 2018
    Publication date: March 28, 2019
    Inventors: Juan Carlos Almagro, William DuBell, Johan Fransson, Jose Pardinas, Gopalan Raghunathan
  • Method of treating idiopathic pulmonary fibrosis by administering human oncostatin M antibodies
    Patent number: 10179812
    Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: January 15, 2019
    Inventors: Juan Carlos Almagro, William DuBell, Johann Fransson, Jose Pardinas, Gopalan Raghunathan
  • Methods of Inhibiting Activity Using Anti-CD27 Antibodies
    Publication number: 20170320957
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: May 16, 2017
    Publication date: November 9, 2017
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • INTERFERON BETA ANTIBODIES AND USES THEREOF
    Publication number: 20170313769
    Abstract: The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFN?). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes.
    Type: Application
    Filed: April 28, 2017
    Publication date: November 2, 2017
    Applicants: PFIZER INC., THE BRIGHAM AND WOMEN?S HOSPITAL, INC.
    Inventors: Stefano V. Gulla, Christine Huard, Janet Elizabeth Buhlmann, Juan Carlos Almagro, Sreekumar R. Kodangattil, Steven A. Greenberg, Edward Roland Lavallie, Eric M. Bennett, Lidia Mosyak, James Perry Hall, Anthony John Coyle
  • Nucleic acid molecules encoding anti-CD27 antibodies
    Patent number: 9683046
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: June 20, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Human Oncostatin M Antibodies and Methods of Use
    Publication number: 20170145090
    Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
    Type: Application
    Filed: February 2, 2017
    Publication date: May 25, 2017
    Inventors: Juan Carlos Almagro, William DuBell, Johann Fransson, Jose Pardinas, Gopalan Raghunathan
  • Polynucleotides encoding human oncostatin M antibodies
    Patent number: 9587018
    Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: March 7, 2017
    Inventors: Juan Carlos Almagro, William DuBell, Johann Fransson, Jose Pardinas, Gopalan Raghunathan